Latest studies
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
This study looks at a new medicine called Evolocumab to see if it can lower the chance of serious heart problems like heart attacks or strokes in people at high risk who haven't had them before. It compares Evolocumab to a dummy medicine.
Adults at high risk of cardiovascular events without prior MI or stroke.Iceland - Active not recruitingPHASE3
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
This study is looking into a new medication called Pelacarsen. It aims to see if this medicine can help people with heart disease who have high levels of a specific type of 'bad' cholesterol (Lipoprotein(a)) reduce their risk of future heart problems.
Cardiovascular Disease and Lipoprotein(a)Iceland - Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
This study looks at how well Medtronic heart devices, like pacemakers and defibrillators, perform over a long time. It helps ensure these devices are reliable and safe for people with heart conditions such as irregular heartbeats or heart failure.
ArrhythmiaBradycardiaHeart FailureSinus TachycardiaIceland - Recruiting
Exploring the hidden burden of living with Glanzmann thrombasthenia
This study wants to hear from people living with Glanzmann thrombasthenia (GT) and their caregivers. We want to understand the daily challenges and feelings of those affected. Your stories can help improve support and understanding for everyone with GT.
Glanzmann thrombastheniaIceland - AuthorisedTherapeutic use (Phase IV)
A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-escalation strategies in patients who respond to treatment.
This study looks at different ways to treat early rheumatoid arthritis, comparing standard treatments with newer biologic medicines. It also explores if medicine doses can be lowered for people who are getting better, aiming to find the most effective and safe long-term approaches.
Rheumatoid ArthritisIceland - AuthorisedTherapeutic exploratory (Phase II)
Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM): A nationwide phase 2 trial of patients with smoldering and active multiple myeloma (MM)
This study is looking at new ways to treat or prevent multiple myeloma, a type of blood cancer. Researchers are testing medicines to see if they can stop the cancer from getting worse in people who have early forms of the disease or are already being treated.
Multiple MyelomaIceland - AuthorisedTherapeutic use (Phase IV)
A Randomized, Non-inferiority Trial Comparing 7-Day Versus 4-Week Esomeprazole Treatment in Patients with Unexplained Dyspepsia
This study compares two ways to treat indigestion: taking esomeprazole for 7 days versus 4 weeks. It aims to see if the shorter treatment works just as well. We want to know if shortening the treatment helps people with ongoing indigestion. It's for adults with unexplained tummy discomfort.
DyspepsiaIceland - Recruiting
Pancreatic Cancer Early Detection Consortium
This study aims to find better ways to spot pancreatic cancer early, especially in people with a higher risk due to family history or specific genetic changes. Researchers will collect health information and samples over time to understand how the disease develops.
Pancreas CancerPancreas CystPancreatic Ductal AdenocarcinomaGenetic PredispositionIceland - Active not recruitingPHASE3
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
This study is testing a new medicine called olpasiran to see if it can help people with heart disease and high levels of a specific fat in their blood, called Lp(a). We want to find out if olpasiran can lower the risk of heart attacks and other heart problems.
Atherosclerotic Cardiovascular DiseaseIceland - Ongoing, recruitingPhase II and Phase III (Integrated)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium in Subjects with Primary Biliary Cholangitis
This study is testing a new medicine, Saroglitazar Magnesium, for people with Primary Biliary Cholangitis (PBC). Researchers want to see if it improves liver test results and is safe. Some people will get the medicine, others will get a dummy pill.
Primary Biliary Cholangitis (PBC)Iceland - Enrolling by invitation
EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV
The EuroSIDA study looks at how HIV affects people in Europe and how treatments work over time. It helps us understand health changes and the impact of new medicines for HIV and related conditions like hepatitis.
HIVHepatitis BHepatitis CAIDSIceland - Active not recruitingPHASE3
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
This study looks at a drug called Olaparib for people in the UK with a specific type of breast cancer linked to a BRCA gene change. It aims to see if Olaparib, given after standard treatments, can help prevent the cancer from coming back.
Breast CancerIceland - RecruitingNA
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
The AURORA study aims to understand advanced breast cancer better. It collects tissue and blood samples from patients across Europe to find out why treatments work or don't. This research could help doctors find the best treatments for each patient in the future.
Metastatic Breast CancerIceland - RecruitingPHASE3
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
This study, called ALLTogether, is for children and young adults aged 0-45 with acute lymphoblastic leukaemia (ALL). It aims to improve survival and reduce side effects by combining the best treatments from several countries and testing new approaches.
Leukemia, Acute LymphoblasticIceland - Recruiting
Fluid Administration and Fluid Accumulation in the Intensive Care Unit
This study looks at how fluids are given to very sick adults in intensive care and if too much fluid builds up. Researchers want to understand why this happens and how it affects patients' recovery, all while collecting information from hospitals worldwide.
Fluid AccumulationFluid TherapyFluid OverloadIceland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with polymyalgia rheumatica (PMR)
This study is testing a new medicine, secukinumab, for polymyalgia rheumatica (PMR). It compares secukinumab with a dummy treatment (placebo) alongside a common steroid medicine to see if it helps reduce symptoms and allows people to use less steroid medicine.
Polymyalgia RheumaticaIceland - Active not recruiting
Micra Transcatheter Pacing System Post-Approval Registry
This study is looking at how a tiny pacemaker, the Micra Transcatheter Pacing System, works in everyday life after it's been approved. It's for people who need this type of pacemaker due to a slow heart rate (bradycardia) to check its safety and how well it works over time.
BradycardiaIceland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
This study is testing a new tablet, Aficamten, for people with a heart condition called non-obstructive hypertrophic cardiomyopathy. It compares Aficamten to a dummy pill to see if it improves how people feel and their exercise ability.
SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHYIceland - Enrolling by invitationPHASE2, PHASE3
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
This study looks at how safe a medicine called aficamten is over a long time for adults with a heart condition called hypertrophic cardiomyopathy (HCM). It's for people who have already tried aficamten in a previous study and want to continue their treatment.
Symptomatic Hypertrophic Cardiomyopathy (HCM)Iceland - RecruitingPHASE4
International Care Bundle Evaluation in Cerebral Hemorrhage Research
This study, called I-CATCHER, is looking into whether a special care package helps people who have a stroke caused by bleeding in the brain (intracerebral haemorrhage). It aims to improve recovery for these patients by testing a new approach to treatment.
Intracerebral HemorrhageIntracerebral HaemorrhageIntraventricular HemorrhageStrokeIceland - Active not recruitingPHASE3
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
This study looks at a new medicine called aficamten for non-obstructive hypertrophic cardiomyopathy (nHCM). It compares aficamten to a dummy medicine (placebo) to see if it improves quality of life, exercise ability, and overall health in adults with nHCM.
Symptomatic Non-Obstructive Hypertrophic CardiomyopathyIceland